UNEEG Medical

Executive Summary

UNEEG Medical is a Danish pioneer in ultra-long-term, subcutaneous EEG monitoring for epilepsy management. Its flagship UNEEG EpiSight System provides continuous, objective seizure and sleep data over years, enabling personalized treatment and improved patient outcomes. By leveraging real-world longitudinal EEG data, the company generates actionable insights for clinicians and drug developers, positioning it at the forefront of precision neurology. Unlike traditional ambulatory EEG systems limited to days, UNEEG's implantable technology offers unprecedented duration and compliance, potentially transforming epilepsy care and clinical trial endpoints. The global epilepsy monitoring market is large and underserved, with over 50 million patients lacking objective long-term seizure data. UNEEG's differentiation lies in its ability to capture high-fidelity data outside the clinic, reducing reliance on patient diaries. The company is likely approaching key regulatory milestones to expand commercial access, such as FDA clearance and CE marking under MDR. Additionally, strategic partnerships with pharmaceutical companies for anti-seizure drug development could unlock significant value. With a strong intellectual property portfolio and a validated clinical need, UNEEG is well-positioned for growth pending successful regulatory and commercial execution.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for EpiSight System60% success
• H2 2026Strategic Partnership for Real-World Data in Epilepsy Drug Trials70% success
• Q4 2026Series C Funding Round to Support Commercial Scale-Up50% success